KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. - Test2 - elhamkhani - TriplyDB

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.

http://www.wikidata.org/entity/Q37694808

about

Super enhancer associated RAI14 is a new potential biomarker in lung adenocarcinoma.Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases

P2860

Q47135291-E4D77AC9-6C06-4124-AFCF-46C205A3A500 Q57788518-862D2AC9-34B0-42A9-8C94-2156C9EB3C31

P2860

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.

http://www.wikidata.org/entity/Q37694808

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

KRAS-mutation status dependent ...... ell cancer preclinical models.

@en

KRAS-mutation status dependent ...... ell cancer preclinical models.

@nl

type

label

KRAS-mutation status dependent ...... ell cancer preclinical models.

@en

KRAS-mutation status dependent ...... ell cancer preclinical models.

@nl

prefLabel

KRAS-mutation status dependent ...... ell cancer preclinical models.

@en

KRAS-mutation status dependent ...... ell cancer preclinical models.

@nl

P1433

Q37694808-0E29CE59-15B0-4535-9C9B-D0AD73A74F68

P1476

Q37694808-D7A65BAE-5447-43C0-9A19-2BE7E5632F99

P2093

Q37694808-421C0007-D786-4236-9DF6-7B28C9672E0B

Q37694808-49E5292A-B824-4547-BE84-29463FD71B80

Q37694808-7841D2C1-528A-48BD-9352-CF7C34C3582F

Q37694808-7C769CDE-5C4E-4159-9006-06188ED86C8C

Q37694808-9D73AD53-7260-4F20-9970-880883E258C6

Q37694808-AD02BFF2-FD87-4662-A7E9-14B404416578

Q37694808-B91137CC-05D9-4AF4-8F10-1F5DC85C75B3

Q37694808-F199D033-413B-47CE-B1AB-41F8E2525272

P2860

Q37694808-01EDAC76-608A-40DE-98AC-968D4A070B2C

Q37694808-02E566C4-D3B7-421D-A82A-6C82615E413A

Q37694808-078EB21F-650D-478D-B30E-85C5A86BD4EE

Q37694808-08E7D45E-EB85-4184-963C-D42251441C9A

Q37694808-0B0FA708-421D-4A93-8BF3-D00EC90C01D3

Q37694808-136C1F68-9262-4E60-B089-ECF6D3BDB088

Q37694808-193B3194-BE58-4F35-B91F-3306A21DA231

Q37694808-212F4DF2-4D38-4086-8DF1-E1B56BF2A985

Q37694808-37AC695A-0EA7-437D-B097-96B8A69D35AC

Q37694808-37EB5048-D03A-42C9-B1C9-0C4AE4C491C8

P304

Q37694808-1D3EA14E-5ACC-4F60-8E28-8CE0C3BD4E54

P31

Q37694808-D0AEC526-9B9C-479E-B487-20BA7ABE0C51

P356

Q37694808-7FAF675D-75C1-4684-8FF8-2E02E913A542

P407

Q37694808-028D545B-354A-4F0F-B068-1257628FD5C8

P433

Q37694808-369B348B-4C5E-4912-A5CA-FD24BB3A1FEB

P478

Q37694808-F996DCF1-4F2C-47CD-97C0-DB924963404F

P50

Q37694808-0E116856-57B6-4F74-8D0A-02DA2C4DF066

Q37694808-D3095FB8-9CE8-49F4-BCD9-F2FAACF540C1

P577

Q37694808-55CD9562-CB0F-44D4-91DE-2FE8F5BBC247

P698

Q37694808-AD3BFD20-357A-476C-8747-CFC4B976FDEB

P932

Q37694808-C5F5186F-E516-486C-AE2F-7716791D3889

P356

ONCOTARGET.12806

P1433

P1476

KRAS-mutation status dependent ...... ell cancer preclinical models.

@en

P2093

Dávid Molnár

http://www.w3.org/2001/XMLSchema#string

István Kenessey

http://www.w3.org/2001/XMLSchema#string

Judit Dobos

http://www.w3.org/2001/XMLSchema#string

József Tímár

http://www.w3.org/2001/XMLSchema#string

József Tóvári

http://www.w3.org/2001/XMLSchema#string

Krisztina Kói

http://www.w3.org/2001/XMLSchema#string

Orsolya Horváth

http://www.w3.org/2001/XMLSchema#string

Vera Izsák

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

Cancer statistics, 2008

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan

Bisphosphonates induce apoptosis in human breast cancer cell lines

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

Rho GTPases and signaling networks

ras oncogenes in human cancer: a review

Ras oncogenes: split personalities

P304

79503-79514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12806

http://www.w3.org/2001/XMLSchema#string

P407

P433

48

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Mihály Cserepes

P577

2016-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27780929

http://www.w3.org/2001/XMLSchema#string

P932

5346731

http://www.w3.org/2001/XMLSchema#string